UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 60

Sortiert nach

Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies

Orphanet journal of rare diseases, 2018-05, Vol.13 (1), p.73-73, Article 73

2018

Volltextzugriff (PDF)

The economic burden of low back pain: a review of studies published between 1996 and 2001

Best practice & research. Clinical rheumatology, 2002-01, Vol.16 (1), p.23-30

2002

Volltextzugriff (PDF)

Ottawa Panel Evidence-Based Clinical Practice Guidelines for Aerobic Walking Programs in the Management of Osteoarthritis

Archives of physical medicine and rehabilitation, 2012-07, Vol.93 (7), p.1269-1285

2012

Volltextzugriff (PDF)

The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis: a knowledge translation randomized controlled trial: part II: clinical outcomes

BMC public health, 2012-12, Vol.12 (1), p.1073-1073, Article 1073

2012

Volltextzugriff (PDF)

Long-Term Antibiotic Cost Savings from a Comprehensive Intervention Program in a Medical Department of a University-Affiliated Teaching Hospital

Clinical infectious diseases, 2004-02, Vol.38 (3), p.348-356

2004

Volltextzugriff (PDF)

Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis

PLoS medicine, 2010-04, Vol.7 (4), p.e1000256-e1000256

2010

Volltextzugriff (PDF)

The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis (OA): a knowledge translation (KT) randomized controlled trial (RCT): Part I: The Uptake of the Ottawa Panel clinical practice guidelines (CPGs)

BMC public health, 2012-10, Vol.12 (1), p.871-871, Article 871

2012

Volltextzugriff (PDF)

The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand

Journal of rheumatology, 2007-01, Vol.34 (1), p.57

2007

Volltextzugriff (PDF)

Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept

Journal of rheumatology, 2008-04, Vol.35 (4), p.662

2008

Volltextzugriff (PDF)

The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology

Journal of rheumatology, 2009-09, Vol.36 (9), p.2045

2009

Volltextzugriff (PDF)

Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case

Journal of rheumatology, 2003-04, Vol.30 (4), p.891

2003

Volltextzugriff (PDF)

Hereditary Angioedema With Normal C1 Inhibitor: US Survey of Prevalence and Provider Practice Patterns

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2023-08, Vol.11 (8), p.2450-2456.e6

2023

Volltextzugriff (PDF)

Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion

Canadian journal of gastroenterology, 2003-05, Vol.17 (5), p.335

Maetzel, Andreas

2003

Volltextzugriff (PDF)

Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on‐demand treatment of hereditary angioedema

Clinical and experimental allergy, 2022-09, Vol.52 (9), p.1059-1070

2022

Volltextzugriff (PDF)

KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results

Journal of allergy and clinical immunology, 2022-06, Vol.149 (6), p.2034-2042

2022

Volltextzugriff (PDF)

Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis

Journal of rheumatology, 2007-05, Vol.34 (5), p.1178

2007

Volltextzugriff (PDF)

A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs

Journal of bone and joint surgery. American volume, 2008-06, Vol.90 (6), p.1197

2008

Volltextzugriff (PDF)

KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic results from a Phase 1 Single Ascending Dose Study

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB39-AB39

2019

Volltextzugriff (PDF)

Cost-effectiveness estimates reported for tumor necrosis factor blocking agents in rheumatoid arthritis refractory to methotrexate--a brief summary

Journal of rheumatology. Supplement, 2005-01, Vol.72, p.51

Maetzel, Andreas

2005

Volltextzugriff (PDF)

Defining therapeutic success in rheumatoid arthritis clinical trials: from statistical significance to clinical significance

Journal of rheumatology, 2004-03, Vol.31 (3), p.411

Maetzel, Andreas

2004

Volltextzugriff (PDF)

Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience

Vaccine, 2010-08, Vol.28 (38), p.6210-6220

2010

Volltextzugriff (PDF)

One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision

Ophthalmology retina, 2019-12, Vol.3 (12), p.1107-1109

2019

Volltextzugriff (PDF)

One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study

Ophthalmology retina, 2019-12, Vol.3 (12), p.1107-1109

2019

Volltextzugriff (PDF)

The challenges of estimating the national costs of osteoarthritis: are we making progress?

Journal of rheumatology, 2002-09, Vol.29 (9), p.1811

Maetzel, Andreas

2002

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(38)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(43)
Life Sciences & Biomedicine
(42)
Science & Technology
(42)
Biological And Medical Sciences
(29)
Rheumatology
(28)
Medical Sciences
(27)
Diseases Of The Osteoarticular System
(18)
Cost-Benefit Analysis
(17)
Female
(16)
Male
(16)
Adult
(12)
Arthritis, Rheumatoid - Economics
(11)
Rheumatoid Arthritis
(11)
Antirheumatic Agents - Therapeutic Use
(10)
Middle Aged
(10)
Health Care Costs
(9)
Inflammatory Joint Diseases
(9)
Pharmacology. Drug Treatments
(9)
Treatment Outcome
(9)
Antirheumatic Agents - Economics
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies

The economic burden of low back pain: a review of studies published between 1996 and 2001

Ottawa Panel Evidence-Based Clinical Practice Guidelines for Aerobic Walking Programs in the Management of Osteoarthritis

The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis: a knowledge translation randomized controlled trial: part II: clinical outcomes

Long-Term Antibiotic Cost Savings from a Comprehensive Intervention Program in a Medical Department of a University-Affiliated Teaching Hospital

Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis

The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis (OA): a knowledge translation (KT) randomized controlled trial (RCT): Part I: The Uptake of the Ottawa Panel clinical practice guidelines (CPGs)

The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand

Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept

The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology

Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case

Hereditary Angioedema With Normal C1 Inhibitor: US Survey of Prevalence and Provider Practice Patterns

Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion

An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial

Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on‐demand treatment of hereditary angioedema

KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results

Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis

A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs

KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic results from a Phase 1 Single Ascending Dose Study

Cost-effectiveness estimates reported for tumor necrosis factor blocking agents in rheumatoid arthritis refractory to methotrexate--a brief summary

Defining therapeutic success in rheumatoid arthritis clinical trials: from statistical significance to clinical significance

Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience

One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision

One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study

The challenges of estimating the national costs of osteoarthritis: are we making progress?

Suchergebnisse filtern